New Study: Hemopressin a Breakthrough for Cannabinoid Field
A joint team of researchers from Brazil and Israel released research days ago that showed that Hemopressin was the first peptide described to have type 1 cannabinoid receptor activity. This had an...
Mike Robinson
3 min read
A joint team of researchers from Brazil and Israel released research days ago that showed that Hemopressin was the first peptide described to have type 1 cannabinoid receptor activity. This had an effect on stopping seizures within the research study on mice as well as prevent neurodegeneration in an experimental model of autoimmune encephalomyelitis.
They concluded that both Hemopressin and hemopressin-related peptides have antinociceptive and anti-inflammatory activities. In a finding that could change how some cannabinoid creations are made in labs, they found that these peptides play a role in the regulation of our food intake, and induce oligodendroglia cell differentiation in neural cultures containing stem cells derived from the subventricular region of newborn mice.
This is a finding of importance as Intracellular hemopressins could function targeting mitochondrial type 1 cannabinoid receptors according to these researching but is this a new finding? In 2007 a study entitled "Hemopressin is an inverse agonist of CB1 cannabinoid receptors" has a title that in itself gives hint that this could be the case. The current study takes the depth of science to the fast moving current molecular level of cannabinoid mediicne therapy.
The 2007 study stated ' Our findings are consistent with recent reports showing that CB1 receptor antagonists can exhibit antihyperalgesic and antinociceptive effects mediated via CB1 receptors in certain pain models. For example, studies have shown that repeated administration of the CB1 receptor antagonist, SR141716, relieved neuropathic pain after sciatic nerve ligature ' which means that this new research could seriously help target new pain medications of the cannabinoid nature in the future.
According to the researchers in the current study next level medications will be made utilizing peptides such as this. They stated that 'Hemopressin self-assembled nanofibrils have potential pharmaceutical applications for target drug-delivery systems.'
Hemopressin as a breakthrough for the cannabinoid field
Andrea S.Heimanna Camila S.Daleb Francisco S.Guimarãescd Ricardo A.M.Reise AmiNavonf Michal A.Shmuelovf VanessaRiolig IvoneGomesh Lakshmi L.Devih Emer S.Ferrofi
Abstract
Hemopressin (PVNFKFLSH in rats, and PVNFKLLSH in humans and mice), a fragment derived from the α-chain of hemoglobin, was the first peptide described to have type 1 cannabinoid receptor activity. While hemopressin was shown to have inverse agonist/antagonistic activity, extended forms of hemopressin (i.e. RVD-hemopressin, also called pepcan-12) exhibit type 1 and type 2 cannabinoid receptor agonistic/allosteric activity, and recent studies suggest that they can activate intracellular mitochondrial cannabinoid receptors. Therefore, hemopressin and hemopressin-related peptides could have location-specific and biased pharmacological action, which would increase the possibilities for fine-tunning and broadening cannabinoid receptor signal transduction. Consistent with this, hemopressins were shown to play a role in a number of physiological processes including antinociceptive and anti-inflammatory activity, regulation of food intake, learning and memory. The shortest active hemopressin fragment, NFKF, delays the first seizure induced by pilocarpine, and prevents neurodegeneration in an experimental model of autoimmune encephalomyelitis. These functions of hemopressins could be due to engagement of both cannabinoid and non-cannabinoid receptor systems. Self-assembled nanofibrils of hemopressin have pH-sensitive switchable surface-active properties, and show potential as inflammation and cancer targeted drug-delivery systems. Upon disruption of the self-assembled hemopressin nanofibril emulsion, the intrinsic analgesic and anti-inflammatory properties of hemopressin could help bolster the therapeutic effect of anti-inflammatory or anti-cancer formulations. In this article, we briefly review the molecular and behavioral pharmacological properties of hemopressins, and summarize studies on the intricate and unique mode of generation and binding of these peptides to cannabinoid receptors. Thus, the review provides a window into the current status of hemopressins in expanding the repertoire of signaling and activity by the endocannabinoid system, in addition to their new potential for pharmaceutic formulations.
This article is published on Science Direct
Thank you for visiting the Global Cannabinoid Research Center website,
–Mike Robinson, Founder – Global Cannabinoid Research Center / GCRC Publications
This article is educational commentary from GCRC. It is not a report of study findings and is not medical advice. Speak with a qualified healthcare professional about your own health.
